echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Enhua pharmaceutical and Hongxing Taikang each invested 25 million yuan to set up a new cardiovascular drug research and development company

    Enhua pharmaceutical and Hongxing Taikang each invested 25 million yuan to set up a new cardiovascular drug research and development company

    • Last Update: 2015-12-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Enhua pharmaceutical announced in the afternoon of December 17 that the company plans to invest 50 million yuan with Beijing Hongxing Taikang Biotechnology Research Institute (hereinafter referred to as "Hongxing Taikang") to establish Zhongjian Yongtai International Pharmaceutical Research Institute (Beijing) Co., Ltd (the final name shall be subject to the name approved by the Administration for industry and commerce, hereinafter referred to as "Zhongjian Yongtai") Both parties intend to contribute 25 million yuan each, accounting for 50% of the registered capital According to the plan, Zhongjian Yongtai, which is to be invested and set up, will be mainly engaged in medical research and experimental development, technology development, technology transfer and technology consultation After its establishment, Zhongjian Yongtai Research Institute will mainly carry out research, application and promotion of major cardiovascular and cerebrovascular diseases, innovative antihypertensive drugs and new clinical diagnosis and treatment technologies Enhua pharmaceutical said that through cooperation between the two sides, it will build Zhongjian Yongtai Research Institute into a National Research Center for the industrialization of cardiovascular innovative drugs and an international research technology platform for the industrialization of innovative drugs The establishment of Zhongjian Yongtai Research Institute will help to further improve the company's R & D strength and level of new drugs in the treatment of cardiovascular diseases, constantly enrich the company's product echelon, and lay a good foundation for the company to achieve sustainable development.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.